medigraphic.com
ISSN 0188-9796 (Print)

2001, Number 2

<< Back Next >>

Rev Endocrinol Nutr 2001; 9 (2)

Factors predicting weight loss whit use of sibutramine

Fanghänel G, Sánchez-Reyes L, Berber A, Cortinas L

Language: Spanish
References: 21
Page: 67-72
PDF size: 170.13 Kb.


ABSTRACT

Objective. To establish the factors predicting weight loss for the patients taking sibutramine and placebo. Research methods and procedures. Statistical analysis of the data from a double-blind, placebo controlled, clinical trial assessing the safety and efficacy of sibutramine. The statistical analysis for each treatment group included multiple linear regression for percentage of weight loss, logistic regression analysis for 5% weight loss, and square chi to compare the percentage of patients achieving the 5% weight loss and ANOVA, Mann-Whitney-Wilcoxon U test or Student’s t test to compare percentage of weight loss considering different subgroups for the factors associated to weight loss. Results. The factors influencing percentage of weight loss in the sibutramine group were weight loss during the first month of treatment, the mean diet adherence in the visual analog scale and the waist-to-hip ratio at baseline, in the placebo group the corresponding factors were weight loss during the first month of treatment and the mean diet adherence in the visual analog scale. The categorical variables influencing the 5% weight loss were the weight loss of ≥ 2 kg during the first month of treatment in the sibutramine group, and the weight loss of ≥ 2 kg during the first month of treatment and the degree of adherence to the diet in the placebo group. The individual analysis of variables disclosed that patients losing 2 kg in the first month of treatment had higher frequencies of patients losing ≥ 5% of baseline body weight and had more percentage of weight loss. Discussion. Losing 2 kg in the first month of obesity treatment is a good independent predictor of success of the treatment. The patients who do not loss 2 kg in the first month of therapy would be non-responder and they must change the treatment approach.


REFERENCES

  1. Press release WHO 46, 12 June 1997. Obesity epidemics puts millions at risk from related diseases. http://www.who.ch/inf/pr/1997/pr97-46 html.

  2. Expert panel on the identification, evaluation and treatment of overweight in adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr 1998; 68: 899-917.

  3. Colditz GA. Economic cots of obesity and inactivity. Med Sci Sports Exerc 1999; 31 (11 Suppl): S663-S667.

  4. Allison DB, Zannolli R, Narayan KM. The direct health costs of obesity in the United States. Am J Public Health 1999; 89: 1194-1199.

  5. Thompson D, Edelsberg J, Kinsey KL, Oster G. Estimated economic costs of obesity to US business. Am J Health Promot 1998; 13: 120-127.

  6. Pi-Sunyer FX. A Review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18; 1006-1035.

  7. National task force on the prevention and treatment of obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-1975.

  8. The North American Association for the Study of Obesity. Guidelines for the approval and use of drugs to treat obesity. Obes Res 1995; 3: 473-478.

  9. Wadden TA, Foster GD, Wang J, Pierson RN, Yang MU, Moreland K, Stunkard AJ, VanItallie TB. Clinical correlates of short- and long-term weight loss. Am J Clin Nutr 1992; 56 (1 Suppl): 271S-274S.

  10. Wabitsch M, Hauner H, Bockmann A, Parthon W, Mayer H, Teller W. The relationship between body fat distribution and weight loss in obese adolescent girls. J Obes Relat Metab Disord 1992; 16: 905-911.

  11. Van Gaal L, Vansant G, Moeremans M, De Leew I. Lipid and lipoprotein changes after long-term weight reduction: the influence of gender and body fat distribution. J Am Coll Nutr 1995; 14: 382-386.

  12. Andersson B, Seidell J, Terning K, Bjorntorp P. Influence of menopause on dietary treatment of obesity. J Intern Med 1990; 227: 173-181.

  13. Kiernan M, King AC, Kraemer HC, Stefanick ML, Killen JD. Characteristics of successful and unsuccessful dieters: an application of signal detection methodology. Ann Behav Med 1998; 20: 1-6.

  14. Sherwood NE, Jeffery RW, Wing RR. Binge status as a predictor of weight loss treatment outcome. Int J Obes Relat Metab Disord 1999; 23: 485-493.

  15. Carmichael HE, Swinburn BA, Wilson MR. Lower fat intake as a predictor of initial and sustained weight loss in obese subjects consuming and otherwise ad libitum diet. J Am Diet Assoc 1998; 98: 35-39.

  16. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obes Res 1995; 3 (Suppl 4): 491S-496S.

  17. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Scwartz SL, Schienbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198.

  18. Weintraub M, Taves DR, Hasday JD, Mushlin AI, Lockwood DH. Determinants of response to anorexiants. Clin Pharmacol Ther 1981; 30: 528-533.

  19. Toornvliet AC, Pijl H, Hopman E, Westendorp RG, Meinders AE. Predictors of weight loss during treatment with d-fenfluramine. J Intern Med 1997; 241: 401-406.

  20. Goldstein DJ, Rampey AH Jr, Roback PJ, Wilson MG, Hamilton SH, Sayler ME, Tollesfon GD. Efficacy and safety of long-term fluoxetine treatment of obesity - maximizing success. Obes Res 1995; 3 (Suppl 4): 481S-490S.

  21. Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000; 24; 144-150.




2020     |     www.medigraphic.com